It’s interesting to note that new research has discovered that altered Nr4a2 expression is likewise linked to the course of AD, and Nr4a2 agonists can speed up the degradation of Aβ by considerably reducing γ-secretase activity by upregulating an Aβ-degrading enzyme (insulin-degrading enzyme). The gene discussed is NR4A2; the disease is Alzheimer disease.